Breast cancer subtypes and outcomes in Colombian women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective cohort analysis of women aged 18 and over with biopsy-confirmed breast cancer and documented molecular subtypes treated at Fundación Santa Fe de Bogotá from 2014 to 2024. It describes the distribution of subtypes (including luminal A, luminal B with/without HER2, HER2-enriched, triple-negative, and HER2-low) and examines associations between clinical, molecular, and treatment factors with overall survival and progression-free survival, with an economic component using micro-costing from the health system perspective. The study uses an umbrella design to enable subtype- and treatment-specific secondary analyses and integrates an assessment of cost of illness by stage and care phase. Interventions observed include standard treatments, CDK4/6 inhibitors, and anti-HER2 therapies as part of routine care. The project aims to inform local practice by linking subtype characteristics to outcomes and costs in Colombia.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients older than 18 years with a histopathologically confirmed diagnosis of breast cancer.
* Treated at Fundación Santa Fe de Bogotá between January 1, 2014 and December 31, 2024.
* Available record of the tumor molecular subtype (luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-enriched or triple-negative), determined by immunohistochemistry and/or in situ hybridization.

Exclusion Criteria:

* Metastatic tumors from another primary site involving the breast (for example, breast metastases from another primary tumor).
* Lesions of uncertain malignant potential or in situ tumors.
* Incomplete or missing information on molecular subtype, treatment received or clinical outcomes.
* Oncology follow-up outside the institution without adequate traceability of clinical outcomes.

Where it's running

• Hospital Universitario Fundación Santa Fe de Bogotá
  Bogotá, Bogota D.C., Colombia Recruiting

Study contacts

• Principal investigator: Erick Andrés Cantor Rizo, MD — Fundación Santa Fe de Bogotá
• Study coordinator: Erick Andrés Cantor Rizo, MD
• Email: erick.cantor@fsfb.org.co
• Phone: +57 601 6030303

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Understanding how tumor shrinkage predicts cancer response in early breast cancer patients

  This study tests if measuring how much breast tumors shrink during chemotherapy can help predict how well the treatment will work for women with early-stage breast cancer.

  Recruiting at 2 sites Phase 2 Baylor Breast Care Center · Houston, Texas and 1 other locations · NCT05020860

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• Gut microbiome differences in people on abemaciclib who do or don't get diarrhea

  This project will compare gut bacteria in people with HR-positive breast cancer who are taking abemaciclib to see if differences are linked to developing diarrhea.

  Recruiting Hubei Cancer Hospital · Wuhan, Hubei · NCT07264998

• Capecitabine with or without elacestrant for ER-positive advanced breast cancer

  This trial will try adding elacestrant to capecitabine to see if it helps people with ER-positive, HER2-negative advanced breast cancer that stopped responding to CDK4/6 inhibitors.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07222215

• Treatment options after targeted therapy stops working in advanced breast cancer

  This study will see how well different treatments work for people with advanced breast cancer who have stopped responding to CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd.

  Recruiting Hunan Cancer Hospital · Changsha, Hunan · NCT07073755

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.